The anti-human immunodeficie~yvirus type 1 (HIV-1) activity of the a-glucosidase 1~nhibitor 6-0-butanoylcastanospermine (MOL 28574) was assessed in combination with the 2',3'-dideoxynucleoside analogues zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). MOL 28574 was also evaluated in combination with the non-nucleoside reverse transcriptase (RT) inhibitor nevi rapine and the HIV proteinase inhibitor saquinavir (Ro-31-8959). Orug interactions were examined by the isobologram technique and by calculating combination indices (CJ.s). In all cases synergistic inhibition of HIV-1 replication was observed. In three-drug combinations, a marked synergistic antiviral effect was also observed, with Col. values in the range 0.35-0.44 for MOL 28574 in combination with AZT and nevirapine, and in the range 0.34-0.67 for MOL 28574 in combination with AZT and saquinavir. Moreover, the combination of MOL 28574 with other drugs did not produce detrimental effects on cell division. MOL 28574 is currently in clinical trials and may have an important role in combination chemotherapy for HIV infections.
Introduction
It is well establishedthat inhibitors of cellular a-glucosidase 1 can modify human immunodeficiency virus (HIV) glycoprotein processing and expression, resulting in vitro in inhibition of virus growth and HIV-induced cell fusion (Walker et al., 1987; Gruters et al., 1987; Tyms et al., 1987; Fleet et al., 1988 Taylor et al., 1991) . a-Glucosidase 1 removes the outer a 1,2-linked glucose residue from precursor oligosaccharide chains during the synthesis of N-Iinked complex glycoproteins (Fuhrmann et al., 1985; McDowell & Schwarz, 1988) . Inhibition of this enzyme activity therefore prevents the late processing events which generate complex and hybrid-type oligosaccharides, maintaining the glycans in a high-mannose configuration. In HIV-infected cells the consequence of incorrectly processed glycans is antagonism of the interaction of the viral glycoproteins, expressed either on the virion or on the infected cell surface, with the cellular receptor CD4. This results in the inhibition of both virus-induced cell fusion and virus infectivity (Ratner, 1992; Taylor etal., 1994) .
Naturally occurring polyhydroxyalkaloids extracted from plants were the original source of such inhibitors. These include castanospermine (CAST), 1-deoxynojirimycin (DNJ), 2R,5R-dihydroxymethyl 3R,4R-dihydroxypyrrolidine (DMDP) and more recently 7,7a-diepialexine (Fellows, 1986; Nash et al., 1990) . The synthesis of derivatives of both CAST and DNJ led to the identification of compounds with much improved antiviral activity Sunkara et al., 1989; Shimizu et al., 1990) with MDL 28574, the 6-0-butanoyl derivative of CAST, being one of the most potent (Taylor et al., 1991) . The increased potency of MDL 28574 compared with the parent molecule is related to the increased cellular uptake of the more lipophilic derivative .
The nucleoside analogues zidovudine (AZT, 3'-azido-2',3'-dideoxythymidine), didanosine (ddl; 2',3'-dideoxyinosine) and zalcitabine (ddC, 2',3'-dideoxycytidine) are currently licensed for the treatment of patients with AIDS. All three compounds, however, are known to induce drugresistant variants (Larder et al., 1989; St Clair et al., 1991; Richman, 1992) and as a result the clinical benefit afforded by these compounds may deteriorate with time. It is likely that future treatment of HIV infections will necessitate the use of antiviral agents, in particularthose with different mechanisms of action, in combination. This approach could generate good synergistic antiviral activity and would minimize potential side-effects as lower concentrations of each drug could be administered.
In the current study we have evaluated the antiviral activity of MOL 28574 in combination with AlT, ddl and ddC. Additionally, we investigated the effect of MOL 28574 in combination with the non-nucleoside reverse transcriptase (RT) inhibitor nevirapine (BI-RG-587) (Merluzzi et al., 1990) and the HIV proteinase inhibitor saquinavir (Ro-31-8959) (Roberts et al., 1990) . After obtaining impressive synergy using MOL 28574 in twodrug combinations we extended the study to the investigation of three drugs used simultaneously. The results indicated that combinations of an a-glucosidase 1 inhibitor, such as MOL 28574, with either a nucleoside or a non-nucleoside RT inhibitor or with an inhibitor of the HIV proteinase activity, or three-way combinations of such drugs, should be considered for HIV-related chemotherapeutic intervention. Furthermore, in an investigation of the response of peripheral blood mononuclear cells (PBMCs) to mitogen, no detrimental effects on cell division within the immune system were observed when MOL 28574 was used in combination with other compounds.
Results

Two-drug combination assays
The MIT cell viability assay, routinely used in a large number of laboratories for the assessment of the antiviral Concentrations (IlM)* giving 50% inhibition of cell death or 50% reduction in p24 production activity of test compounds, was adapted for the purpose of this combination study. Using this method it was apparent that total protection of HIV-1-infected MT-4 cells, after treatment with MOL 28574 or other inhibitors of a-glucosidase 1, was not observed. This was in contrast to the situation for inhibitors which act at alternative targets in the HIV replication cycle such as inhibitors of the HIV RT or proteinase. Despite the fact that MOL 28574 did not totally protect the cells, >50% protection could be consistently achieved, and typical results are illustrated in Fig. 1f . Thus, it was possible, using this assay, to calculate an IC so value for MOL 28574 alone and to study its effects in conjunction with other compounds with known anti-HIV-1 activity. The mean IC so for MOL 28574 using this cell viability assay was 49.7 11M ± 20.6 11M (n= 9).
MOL 28574 initially was studied in combination with AlT, as it had been previously reported that CAST was synergistic with this RT inhibitor (Johnson at al., 1989a) .
The concentration ranges studied were 250-211M MOL 28574 and 0.1-0.0003 11M AlT, using a series of doubling dilutions. It was apparent from the results that the addition of low concentrations of AlT could significantly alter the antiviral activity of MOL 28574 and vice versa. This is illustrated by the dose-response curves shown in Fig. 1 . When the IC so values determined for each combination of compound were used to calculate C.1. values these were in the range 0.45-0.62 (Table 1 ). It was concluded that MOL 28574 and AlT synergistically protected MT-4 cells from HIV-1-mediated cell death. The degree of synergy between the two compounds was more clearly illustrated by the construction of an isobologram which had the char- the characteristic concave shape (Fig.2a ). The antiviral effects of MOL 28574 and AZT in combination were also studied by measuring the inhibition of p24 production in HIV-1-infected H9 cells. The results (Table 1) were consistent with those obtained using the MTI assay. This was evidence that the quantification of cell Viability was a reliable method for the assessment of drug interactions, and the MTI assay was subsequently used for the assessment of the antiviral effects of MOL 28574 in combination with a number of other compounds.
MOL 28574 also proved to interact synergistically with the other 2',3'-dideoxynucleoside analogues ddl and ddC. Chequerboards of two drugs were created using concentrations of ddl ranging from 100 to 0.01 11M, concentrations of ddC ranging from 10 to 0.001 11M and concentrations of MOL 28574 in the range 300-0.1 11M, using a series of half log dilutions. In each case the C.1. values, which were in the range 0.52-0.75 for ddl and 0.46-0.82 for ddC (Table 2) also synergistic with the non-nucleoside RT inhibitor nevirapine (concentration range 3-0.0003 flM), with C.1. values in the range 0.40~0.78 (Table 2 and Fig. 2e ). Consistent with this result was the synergy we observed when the a-glucosidase 1 antagonistwas combinedwith a second non-nucleoside RT inhibitor, the HEPT derivative MKC-442 (Brennan et al., 1995) .
Finally, MOL 28574 was also studied in combination with the peptidomimetic HIV proteinase inhibitor saquinavir, which contains a hydroxyethylamine transition state moiety in place of the scissile bond. As anticipated, because of the different mode of antiviral action, synergy was usually observed with C.1. values recorded in the range 0.34-0.53 (Table 2 and Fig.2d ). It was apparent, however, that there was variability between assays, and in some instances only an additive effect was recorded when saquinavir and MOL 28574 were used in combination. The reason for this variability has not been determined. In support of the observation that there is increased antiviral effect when a proteinase and an a-glucosidase 1 inhibitor are used in combination, synergistic antiviral activity was also recorded when MOL 28574 was used in combination with a second HIV proteinase inhibitor (data not shown) of the difluorostatone type, MOL 73669 (Van Oorsselaer et al., 1994) .
Three-drug combination assays
As an extension of the observations made in the two-drug combination experiments described above, two different three-way combinations consisting of MOL 28574 (concentration range 100-1 flM) and AZT (0.1-0.001 flM) with either saquinavir(0.03-0.0003 flM) or nevirapine(1-0.01 flM) were investigated. The MTI cell viability assay was used to calculate the IC so values for each antiviral agent alone and with fixed concentrations of the other two compounds. The calculated C.1. values for a selection of the different combinations are shown in Tables 3 and 4 . 0.003(10) 0.0007 (8,5) 10(6.5) 0.003 (10) 0.lJ03 (2) 4.8 (13.5) 0.01 (3) 0.0003 (20) 2.8(23) 0.015 (2) 0.0003 (20) 1 (65) Combination index **p Consistent with previous two-way experiments, MDL 28574 in combination with either AZT, saquinavir or nevirapine, and AZT in combination with nevirapine, showed synergy. In contrast, but consistent with previous observations using this cell viability method, AZT and saquinavir (see Fig.2f ) had only an additive antiviral effect when used together. When MDL 28574 was combined with AZT and saquinavir (C.1. values in the range 0.34-0.67) or with AZT and nevirapine (C.1. values in the range 0.35-0.44) the synergistic effect was marked (see Tables 3 and 4 ). Overall, the results showed that, by using three different types of inhibitor in combination, the concentrations of each could be substantially reduced when compared with the concentrations required to prevent cell death when compounds were used singularly.
Effect of MOL 28574 in combination with other drugs on lymphocyte function
l .:'f! In the antiviral assays described above, no cytotoxicity was observed at the concentrations used, for any of the compounds used singularly or in combination. This lack of cytotoxicity, however, does not disclose any risk of potential effects on cellular immune function. The ability of freshly recovered PBMCsto proliferate in response to the mitogen concanavalin A, in the presence of the various drug combinations which had shown synergistic antiviral activity, was therefore investigated. Human PBMCs were stimulated for 72 h at 37 DC and lymphocyte proliferation was measured by the uptake of [3Hl-thymidine. The concentration of MDL 28574 which caused a 50% reduction in thymidine incorporation was 780±99~M (n=6). The nucleoside analogues AZT, ddC and ddl caused a 50% reduction in lymphocyte stimulation at mean concentrations of 11, 19.5 and 800~M, respectively, and these endpoints were not affected in combination with up to 100~M MDL 28574. Similarly, the 50% cytotoxic concentrations (CC 5 0 ) of nevirapine (>100~M) and saquinavir (10~M) were not altered by the addition of 100~M MDL 28574. In the case of AZT, which could potentially antagonize the utilization of [3Hl thymidine, a similar mean CC 5 0 (21~M) was obtained using deoxy-I''Hl-cytidine, and cell numbers were significantly reduced at concentrations above this. For studying the effects of three drugs together we com" bined 100~M MDL 28574 with 1~M AZT, and either 1~M saquinavir or 10 11M nevirapine, and noted no reduction in the incorporation of [3Hl-thymidine, compared with untreated cells. Overall, these results indicated that, at the low concentrations of drugs required for synergistic antiviral activity, cytotoxic or detrimental effects on mitogen-induced cell division within the immune system should not occur.
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Discussion
Optimal HIV therapy will almost certainly require the use of combinations of drugs. In fact, the use of antibiotics and antineoplastic agents has demonstrated that combination therapy with several agents is often the most effective approach and results in equal or superior efficacy with reduced toxicity at lower doses for each agent. To date, numerous combinations of compounds, with the same (convergent) or different (divergent) antiviral targets, have been identified which exhibit synergistic anti-HIV-1 activity, at least in cell culture (Hartshorn et al., 1986; Johnson et al., 1989b; Johnson et al., 1990; Dornsife et al., 1991; Pan et al., 1992; Koup et el., 1993) . Some groups have proposed that convergent combination therapy may be the most appropriate for the treatment of HIV infections, by virtue of the fact that multiple mutations in the same viral gene should cause the total compromise of an essential viral enzyme function. Theoretically this should prevent the development of multi-drug resistance (Chow et al., 1993 ). It appears, however, that multi-drug-resistant variants can still be selected during such combination therapy (Emini et al., 1993; Larder et al., 1993) . Divergent therapy, the more conventional approach for combination regimens, uses antiviral agents that have different mechanisms of action, do not share cross-resistance, and have different dose-limiting toxicities. Using this divergent approach, our results demonstrated the synergistic interactions of the a-glucosidase 1 inhibitor MDL 28574, with both nucleoside and non-nucleoside RT inhibitors, as well as HIV proteinase inhibitors, in vitro as two-drug combinations. In addition, the three-drug combinations of either MDL 28574, AZT and saquinavir or MDL 28574, AZT and nevirapine showed marked synergy. Synergistic interactions were only determined at 50% inhibition levels because, using the MIT cell viability assay, MT-4 cells could not be totally protected by treatment with MDL 28574 alone. This meant that we were unable to calculate an IC go value for MDL 28574, or to determine the degree of synergy with other compounds at 90% inhibition levels, where in general greater synergy is often observed. Although the precise reason for this lack of total protection by MDL 28574 is unclear, it is likely to be related to the novel mechanism of action of a"glucosidase 1 inhibitors. Such compounds do not inhibit the first round of viral replication in a culture, but result in the production of virions with 10-1 OO-fold reduced infectivity (Taylor et al., 1991 , which subsequently inhibits virus spread. The fact that the production of infectious virus is not totally prevented may explain why cells cannot be completely protected when such compounds are used as single agents. Pretreatment of MT-4 cells with MDL 28574 did not improve the protective effect, and similar findings were observed using different strains of HIV-1.
Similar results to those reported here were obtained for N-butyl-DNJ (SC-48334), another inhibitor of a-glucosidase 1, which also had synergistic antiviral activity in vitro in combination with the nucleoside RT inhibitor AZT or ddl (Ratner & Vander Heyden, 1993) . In this study antiviral effects were determined by measurement of the yield of infectious HIV and suppression of HIV-1-associated RT activity. Most interestingly, preliminary results indicate that N-butyl-DNJ and AZT administered in combination may be efficacious in the treatment of patients with AIDS (Fischl et al., 1994) . Although it has not been reported whether virus isolated from the treated individuals is still sensitive to the two drugs, encouragingly the results indicate that in vitro observations can be relevant to the clinical situation.
In addition to synergy and reduced toxicity, one other advantage of using drugs in combination is that the likelihood of the emergence of drug-resistant strains of HIV is reduced. This has been one of the main problems encountered with the use of nucleoside analogues, when used as single agents, in the chemotherapy of HIV infections (Richman, 1992; Larder et al., 1989; Sarver et al., 1992) . Similarly, phase 1/11 clinical trials involving nonnucleoside RT inhibitors (Richman et al., 1992; Saag et al., 1993) and HIV proteinase inhibitors (H. Jacobsen et al., Hoffmann-La Roche, personal communication; Emini et el., Merck Research Laboratories, personal communication) have also indicated the emergence of such mutants. Although MDL 28574 has no potential for selectivity, phase I clinical trials indicate that it is well tolerated, and the fact that this compound inhibits a cell-encoded rather than a virus-encoded enzyme may be advantageous with respect to preventing the induction of viral drug resistance. With these factors in mind we propose that MDL 28574 could be of benefit when used in combination with other antiviral agents for the treatment of HIV infections.
Materials and Experimental Procedures
Compounds MDL 28574 was synthesized from CAST as previously described (Liu et al., 1990) . Saquinavir and ddC were provided by Roche Products Ltd and nevirapine by Boehringer Ingelheim. AZT and ddl were purchasedfrom the Sigma Chemical Co.
Cells and virus
Both the human T-cell lymphoma line H9 and the human T-cell Iymphotropic virus type 1-transformed cell line MT-4 were obtained from the MRC AIDS Directed Programme (ADP) Reagent Project, National Institute for Biological Standards and Control, Potters Bar, UK. Cells were grown in RPMI 1640 (Gibco) supplemented with 10% fetal calf serum, glutamine (290Jlg mr"), penicillin (100 units mr') and streptomycin (50Jlg rnr '). The HIV-1 strain RF was also obtained from the ADP. Virus stocks were propagated in H9 cells and stored as cell-free supernatant fluids in liquid nitrogen. The 50% tissue culture infective dose (TCID so) of virus stocks was determined by endpoint titration in either H9 or MT-4cells.
Drug combination assays.
MIT cell viability assay. The 3-(4,5-dimethyl-2-yl)-2,5diphenyl-tetrazolium bromide (MTT) cell viability assay originally published by Pauwels et al. (1988) was adapted for analysing the anti-HIV-1 effects of drug combinations. Assays were carried out essentially as described elsewhere (Brennan et al., 1995) . Briefly, for two-drug combinations chequerboards of different combinations were generated in 96-well cell culture plates, by titrating one drug horizontally and the other drug vertically across the plates. For three-drug combinations, chequerboards of two drugs were created on a background of a fixed concentration of the third compound. The viability of HIV-1 RF-infected MT-4 cells was assessed after 5 days, using MTT, and the plates were read at 540 nm. Raw ASCII data from the plate reader were captured by Ultroterm and further processed by Microsoft Excel, with minimal user intervention. A series of linked Excel macros were written to parse, calculate the means and standard deviations of O.D. values, and then plot dose-response graphs.
p24 ELISA. The second_method of analysing the effects of drug combinations involved measuring levels of p24 viral core antigen in the supernatant fluids of treated and untreated cells. In this assay, chequerboards of drug combinations were achieved in a similar manner to that described above. H9 cells were infected with HIV-1 RF at a multiplicity of infection of 0.0001, washed and distributed at a concentration of 5 x 10 4 cells per well. The culture plates were incubated at 37°C for 5 days and the cell-free culture fluid was assayed for p24 using a commercial ELISA assay (Coulter). From the data, dose-response curves for inhibition of p24 production were plotted.
Analysis of results
From the series of dose-response curves that were generated, 50% inhibitory concentrations (ICsos) for each drug at a fixed concentration of the other as well as for each drug alone were determined. These IC so values were used to construct isobolograms (Berenbaum, 1989; Suhnel, 1990) and to calculate a combination index (C.I.) using the general isobole equation as described by Berenbaum (1989 For three-drug combinations, dose-response curves were generated for each drug alone, as well as for each drug at fixed concentrations of the other two. These dose-response curves were used to calculate IQsos, and C.1. values were calculated using the following equation:
(D)A (D)s (Dle C.1. = (DX)A + (DX)s + (DXle as previously described (Berenbaum, 1989) . Where (DX)A' (DX)s and (DXle are the ICsos of drugs A, Band C alone, and (D)A' (D)s or (Dle are the concentrations of drugs A, Band C in combination giving 50% protection of the cells.
Human lymphocyte proliferation
Human PBMCs were isolated by gradient centrifugation from acid citrate dextrose-treated buffy coat (North London Blood Transfusion Centre, Colindale, London) and were distributed into 96-well round-bottomed plates at a concentration of 2 x 10 s cells per well. The cells were stimulated with concanavalin A (2.5~g rnr') (Boehringer Mannheim), in the presence or absence of different concentrations and combinations of drugs, and incubated for 48 h at 37 DC. The cells were then labelled with [3Hl-thymidine (Amersham) (1~Ci per well) for 24h and radiolabelincorporation was assessed bxJell harvest onto glass fibre paper followed by measurement ir~' a~-spectrometer. For assays involving the use of AZT, which would antagonize the uptake of thymidine, deoxy-[5-3Hl-cytidine incorporation and cell counts were assessed in parallel cultures.
